Fig. 2: GSK’074 inhibits necroptosis in various cell types.

a–c MOVAS cells were treated with 30 ng/ml TNFα plus 60 μM zVAD and compounds indicated for 6 h. Cells were then stained with 7-AAD and analyzed by flow cytometry. Necrotic cells were identified as 7-AAD+. d Mouse primary smooth muscle cells were treated with 100 ng/ml TNFα plus 60 μM zVAD and 10 nM GSK’074 for 24 h. Cells were then stained with 7-AAD and analyzed by flow cytometry. e Mouse bone marrow derived macrophages (BMDM) were treated with 10 ng/ml LPS plus 50 µM zVAD and 10 nM GSK’074 for 24 h. Cell viability was detected by CellTiter-Glo. f Human colorectal adenocarcinoma cell line HT-29 cells were treated with 20 ng/ml TNFα plus 200 nM Smac mimetic, 20 μM zVAD, and 10 nM GSK’074 for 24 h. Cells were then stained with 7-AAD and analyzed by flow cytometry. Data were presented as mean ± S.D. n = 3. *P < 0.05